|
Synonyms: ADC 122 [3]
Compound class:
Antibody
Comment: ABBV-3373 is a investigational antibody-drug conjugate (ADC) in which a novel glucocorticoid receptor modulator payload is linked to the anti-TNαF antibody adalimumab [3]. It was designed to modulate TNF-mediated inflammatory pathways by delivering the glucocorticoid directly into activated immune cells that express membrane-bound TNFα, as a treatment for immune-mediated diseases such as rheumatoid arthritis.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| ABBV-3373 is being evaluated for safety and efficacy in patients with moderate to severe rheumatoid arthritis (RA) [1-2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03823391 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA) | Phase 2 Interventional | AbbVie | ||
